GlassScriptPhysician profile
Kimberly Streiff
NPI 1447504295
$5,146.71
in general payments reported to CMS, 2019-2025
16 companies · $1,804 in 2025
The $1,804 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.64 · 2022: $560 · 2023: $1,555 · 2024: $1,163 · 2025: $1,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,441 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,440.53 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $845.25 | 2021-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $799.17 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $678.15 | 2021-2025 | Rexulti |
| Alkermes, INC. | $636.61 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $390.88 | 2021-2025 | |
| Axsome Therapeutics, INC. | $367.94 | 2022-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $298.85 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $289.37 | 2022-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $249.27 | 2024-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $200.15 | 2023-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $125.58 | 2023 | Andexxa |
| E.R. Squibb & Sons, L.L.C. | $116.14 | 2024-2025 | Cobenfy |
| Neurocrine Biosciences, INC. | $71.70 | 2024-2025 | Ingrezza |
| Corium, LLC | $30.83 | 2025 | Azstarys |
| Indivior INC. | $23.42 | 2024 | Perseris |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $23.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Streiff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.